Name (Synonyms) | Correlation | |
---|---|---|
drug2144 | SARS-CoV2 serum antibody testing Wiki | 1.00 |
Name (Synonyms) | Correlation | |
---|---|---|
D045169 | Severe Acute Respiratory Syndrome NIH | 0.05 |
D018352 | Coronavirus Infections NIH | 0.04 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
The purpose of this study is to evaluate the safety of administration of plasma containing antibodies to the SARS-CoV-2 virus (i.e., convalescent plasma) and if it is able to prevent disease or lessen the severity of disease in individuals who are at high risk of developing COVID-19 due to a recent exposure. This study will also measure the level of anti-SARS-CoV-2 antibodies in patient's blood after the administration of the convalescent plasma.
Description: Proportion of subjects with grade 3 and 4 adverse events during the study period
Measure: Safety of treatment with high-titer anti-SARS-CoV-2 plasma as assessed by adverse events Time: 28 daysDescription: Descriptive analysis of these outcomes, e.g. disease worsening as defined by hospitalization, need for supplemental oxygenation, respiratory distress, requirement for mechanical ventilation, and death
Measure: Proportion of subjects with disease worsening event Time: 28 daysDescription: Anti-SARS-CoV-2 antibody titer changes
Measure: Pharmacokinetics of anti-SARS-CoV-2 antibodies as defined by changes in antibody titers Time: Up to 28 daysDescription: This will be assessed by the presence or absence of anti-SARS-CoV-2 antibody titers. Antibody titer will be collected one time between 60-120 days.
Measure: Proportion of subjects with a natural antibody response to SARS-CoV-2 infection Time: 60-120 days